Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06570954 · ClinicalTrials.gov registry record · NA
Retraining and Control Therapy (ReACT)- Adults
A NA study of Convulsion, Non-Epileptic, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06570954 is a NA study of Convulsion, Non-Epileptic that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 50 participants, below the 359-participant average among 4 other Convulsion, Non-Epileptic trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06570954, a NA study of Convulsion, Non-Epileptic, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of adult psychogenic non-epileptic seizures (PNES, episodes resembling epileptic seizures but with no correlated epileptiform activity). 19 years and older participants diagnosed with PNES who are treated at UAB FND clinic will engage in twelve sessions of ReACT. Participants will be randomly assigned to one of three conditions: no wait, 3-month waiting period, 6-month waiting period. Sense of control over actions will be measured by the magic and turbulence task, a well-validated measure of sense of control. Participants will complete the cold pressor test (CPT) in which participants hold their hand in cool water for as long as possible up to 3 minutes. Catastrophic symptom expectations in response to the CPT will be measured by Pain Catastrophizing Scale (PCS), pain tolerance (time with hand in water) and cortisol response. Target assessments occur 7 days before treatment and 7 days after the 12th treatment session. Participants randomized to the 3-month and 6-month waiting period will also complete these measures one additional time immediately before the beginning of their waiting period. Long term follow-up assessments will occur at 2 months, 6 months and 12 months after the 12th treatment session. PNES frequency will be measured from 30 days before to 12 months after treatment. Participants randomized to the 3-month or 6-month waiting period conditions will log weekly PNES episodes until the start of therapy.
Conditions Studied
Interventions
- BEHAVIORAL ReACT
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06570954
The ClinicalTrials.gov registry entry for NCT06570954 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 359-participant average among 4 other Convulsion, Non-Epileptic trials with a reported enrollment target (86% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Convulsion, Non-Epileptic appearing as the primary indexed condition, and to 1 intervention - of which ReACT is the first listed.
NCT06570954 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06570954 about?
NCT06570954 is a clinical study titled "Retraining and Control Therapy (ReACT)- Adults". The purpose of this study is to assess sense of control and catastrophic symptom expectations as targets for Retraining and Control Therapy (ReACT- an intervention focused on changing behaviors and thoughts) for treatment of adult psychogenic non-epileptic seizures (PNES, episodes resembling epilept...
What is the current status of trial NCT06570954?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-04-10. Estimated completion is 2027-12-31.
What conditions does trial NCT06570954 study?
This clinical trial studies the following conditions: Convulsion, Non-Epileptic.
What interventions are being tested in trial NCT06570954?
The interventions under investigation include: ReACT (BEHAVIORAL).
Who is sponsoring clinical trial NCT06570954?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06570954 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Convulsion, Non-Epileptic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retraining and Control Therapy (ReACT) R33 Phase
RECRUITING · NA
-
Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNES
RECRUITING · NA
-
A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional Seizures
RECRUITING · NA
-
Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.